| |
| |
A ONE-DAY EDUCATIONAL RETREAT FOR C-SUITE HEALTHCARE
EXECUTIVES |
The next ten years in cancer will continue to be complex, expensive and miraculous. This program will chart the scientific, economic and cultural history of cancer and connect to the headlines of today. It will provide you with the knowledge to project future demand and resource needs to successfully manage this complex illness in the coming years.
|
|
|
| |
|
|
|
|
|
|
|
| |
| |
| Overview |
| |
How much do you know about the new science/discoveries, trends in treatments and the business behind cancer care? The changes taking place in cancer are breathtaking from immunotherapy and precision medicine; to advances in surgical procedures and radiation therapy; to new modalities of treatment such as Car-T. How have these developments changed the practice of cancer care? What advances are being made to provide integrated and comprehensive care?
What will your strategy be in cancer? How will it fit into your overall strategy? How will you balance quality, patient satisfaction and cost? How will you project future demand and resource needs?
All of these topics will be explored in-depth by leading experts in the field in a one-day highly interactive classroom style program limited to 50 attendees.
This program is developed by Meyer Consulting, an international health care firm that produces the very successful Cancer Care at the Crossroads Summit each year in New York City. |
| |
|
|
| |
|
|
|
|
|
|
|
|
|
| |
| JOHN GUNN |
John was recruited to Memorial Sloan Kettering Cancer Center as their Chief Financial Officer and was promoted to Chief Operating Officer in 1987 where he served in that role for 27 years until his retirement in 2015.
John is one of the leading experts on the business and financial aspects of cancer care. He serves on several health care company Boards and has published in several journals on the subject of cancer care delivery in a coordinated manner – which he believes is the best way of reducing the cost of care and improving patient outcomes. |
|
|
| |
|
|
|
|
|
|
|
| |
| RAZELLE KURZROCK, MD, PhD |
Razelle is known for developing the largest Phase 1 clinical trials department in the nation at MD Anderson Cancer Center. She is the Chief, Division of Hematology and Oncology, Director, Center for Personalized Cancer Therapy and Senior Deputy Center Director at University of California San Diego Health.
Dr. Kurzrock is one of the world's leading experts on future trends in new science and discoveries in cancer care. She has overseen the conduct of over 500 clinical trials, and been the principal investigator on seminal early trials of eight drugs that have gone on to FDA approval. She has extensive expertise in precision medicine, especially as it relates to genomics and immunotherapy. Dr. Kurzrock is a frequent speaker nationally and internationally, and has published over 700 scientifically reviewed articles, as well as seven books. |
|
|
| |
|
|
|
|
|
|
|
| |
| RON WINSLOW |
Until last year Ron was the Senior Health correspondent for the Wall Street Journal. He has covered cancer discoveries and treatments for over 30 years. In this role he has seen the changes occurring in cancer and how those changes have been covered by the press and impacted consumers.
Ron is an expert in understanding the challenges around public perceptions of cancer as well as approaches to reporting discoveries, treatment and allocation of resources, and the impact media and advertising have on patients and families. |
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
| STEPHEN GRUBBS, MD |
Steve is the Vice President of the Clinical Affairs Department of American Society of Clinical Oncology. Prior to joining ASCO, Steve served for over 20 years as managing partner for his independent medical practice, Medical Oncology Hematology Consultants and was a practicing medical oncologist at the Helen F. Graham Cancer Center.
The ASCO Clinical Affairs department supports practicing oncologists both domestically and internationally through ASCO quality programs, practice business intelligence and support, value-based care consulting, and practice education. He is a Clinical Assistant Professor of Medicine of the Thomas Jefferson Medical School faculty.
Dr. Grubbs has served as a member of the National Cancer Institute Clinical Trials Advisory Committee, co-chair of the Clinical Trials Subcommittee of the NCI Community Cancer Centers Program (NCCCP), and the Institute of Medicine Committee on Cancer Clinical Trials and the NCI Cooperative Group Program. He has been an active community based clinical trial investigator with the NCI sponsored CALGB, ECOG, NSABP, and Alliance Cooperative Groups since 1984 and is the recipient of the 2007 Association of Community Cancer Centers David King Community Clinical Scientist Award.
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
| MICHAEL MEYER |
Mike is the President of Meyer Consulting. He has spent his career serving healthcare organizations in their strategic and human capital initiatives. Over these years he has worked for many of the leading cancer centers in the world including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center and the Mayo Clinic.
Mike has worked across the health care field, with clients as diverse as the Blue Cross Blue Shield Association and other health plans to leading health systems and large medical groups. He is the founder and host of the Cancer Care at the Crossroads Summit held each year in New York City. Mike was the strategic advisor to the WIN Consortium for personalized cancer medicine based in Paris.
He has grown several companies successfully and serves on the Board of Summit, one of the largest provider owned multispecialty groups in the US. He is the former board chair and co-founder of the Institute for Mental Health Research, the only statewide organization of its kind in the US which partners with and funds Arizona researchers and direct care providers in their broad-based and innovative mental health research. |
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
DINNER SPEAKER
MICHAEL KUPFERMAN, MD |
Dr. Michael Kupferman is the Senior Vice President of Clinical and Academic Network Development at the University of Texas MD Anderson Cancer Center. In this role, Dr. Kupferman leads the development, management and growth of clinical oncology and research programs across the Cancer Network, inclusive of domestic and international partnerships. He is a Professor in the Department of Head and Neck Surgery and is an internationally-recognized expert in Head and Neck Oncology, with expertise in the surgical management of pediatric head and neck cancers and skull base tumors. His clinical practice focuses on upper aerodigestive tract cancers, melanoma, salivary gland and skull base tumors, as well as robotic surgery of the head and neck.
He obtained his medical degree from the University of Pennsylvania School of Medicine and completed residency in Otolaryngology & Head and Neck Surgery at the Hospital of the University of Pennsylvania. He completed a fellowship in advanced Head and Neck Surgical Oncology at MDACC, and he received his MBA from the Kellogg School of Management, Northwestern University.
He has published over 125 peer-reviewed manuscripts and book chapters, and his laboratory research in the mechanisms of metastasis has been funded by the NIH, ACS, AHNS, AAO-HNSF and numerous private foundations. |
|
|
| |
|
|
|
|
|
|
|
The latest developments in cancer care research, prevention, delivery and cost/pricing |
|
|
|
|
|
|
The future of cancer treatment and the challenges and opportunities |
|
|
|
|
|
|
How to project future demand and resource needs |
|
|
|
|
|
|
The prevailing health care business models/strategies and how cancer fits in (or doesn't) |
|
|
|
|
|
|
The history of cancer discoveries, treatments and cancer economics (how we got here) |
|
|
|
|
|
|
How the "new science" of cancer care will change the standard of care for patients |
|
|
|
|
|
|
About genomics, precision medicine, biosimilars and new modalities like Car-T |
|
|
|
|
|
|
What is being done to create integrated, coordinated care to reduce side effects, improve outcomes and reduce costs |
|
|
|
|
|
|
The use of large data, analytics and the future of AI to improve outcomes and reduce costs |
|
|
|
|
|
|
How pharma is approaching this "new science" of drug discoveries |
|
|
|
|
|
|
How providers, health plans and governments are facing the challenges provided by all these disruptive changes. The prevailing payer models |
|
|
|
|
|
|
The behavioral economics of cancer – how patients and families deal with this disease |
|
|
|
|
|
|
The role of functional medicine and alternative/complementary treatments |
|
|
|
|
|
|
What role the media has and is playing in this environment and how stories get developed |
|
|
|
|
|
|
The philosophical aspects of cancer care and the allocation of resources |
|
|
|
| |
| Schedule |
| |
The program will begin with a dinner for all attendees Thursday night followed by the full day program on June 14.
The day will be broken up into five sections each taught by one of the experts listed above. |
| |
|
|
|
| |
| The Venue |
| |
The Cedar House is an award winning hotel inspired by its setting high in the Sierra Nevada Mountains, nestled in the Martis Valley, just minutes from Historic Downtown Truckee and Lake Tahoe.
The Cedar House offers unparalleled attention to all events and conference details, and regularly plays host to corporate groups such as Google, Novartis, Driscoll, Sales Force, Facebook and more. The Reno International Airport is only 35 miles away.
Visit The Cedar House Website (http://www.cedarhousesporthotel.com/) |
| |
|
|
|
